Intuitive Surgical enters the final stretch before its October 20 earnings with a genuine tension in the data: short interest has stabilised near a recent high while options traders continue to lean bullish, keeping the two camps pointing in opposite directions twenty days out from the print.
The short-side picture has changed little since last week's convergence note flagged the reversal. Short interest settled at 2.31% of free float on September 29, effectively flat on the week after the sharp 10.5% weekly jump reported then. The rebuild from mid-September's trough around 7.2 million shares is now fully consolidated near 8.2 million. That's still a low absolute level, but the pace of the original move and the subsequent refusal to unwind tells a different story from the steady covering trend seen through early September. Borrowing costs have eased back to 0.34%, down roughly 12% on the week and a quarter below where they were a month ago. Borrow availability remains extraordinarily loose at nearly 8,700% of shares short, well above even the 52-week floor of 5,772%, so there is no friction in the lending market limiting new short activity. Shorts are holding rather than being squeezed out.
Options traders are not reading the same script. The put/call ratio edged up to 0.80 by week's end, but remains below its 20-day average of 0.82 and nearly a full standard deviation lighter on puts than usual. The ratio has been drifting back toward its mean after touching more call-heavy levels in the 0.76 to 0.78 range mid-week, and is well short of the 52-week high of 1.23. Call-side demand that built sharply through September has moderated but has not reversed. The divergence between a short book that has rebuilt and an options market that remains relatively constructive is the clearest tension heading into October 20.
The Street sits somewhere between the two camps. The consensus is a hold, though the majority of analysts with buy-equivalent ratings carry targets in the $450 to $500 range against a current price of $412. Oppenheimer upgraded to Outperform in August with a $500 target. JP Morgan and Raymond James both trimmed targets sharply after July's results but kept positive ratings, as did Wells Fargo and Piper Sandler. The July quarter was the wound: the stock fell 11% on the day and 15% over the following week. Those moves explain the target cuts and the current valuation caution. At a forward P/E of 35 the stock is priced for recovery rather than a repeat stumble, and the EV/EBITDA of 24.6 has eased slightly over the past month as the price has recovered 10%. One target from HSBC, flagged in the data at $931, appears inconsistent with current price levels and peer targets and is omitted here. Factor scores are broadly neutral: EPS momentum over 90 days ranks in the 65th percentile, days-to-cover in the 67th, and the short score rank in the 61st. The valuation factor is the weakest read, ranking in just the 13th percentile on EV/EBIT.
Insider activity over the past 90 days adds texture without changing the story. The net 90-day position is a sale of roughly 12,600 shares worth about $5 million, but all of it flows through pre-arranged 10b5-1 plans. VP Corporate Controller Fredrik Widman exercised options and sold the resulting shares in mid-September, a standard liquidity transaction. EVP Mark Brosius has been selling small parcels, between 23 and 77 shares at a time, at regular intervals since August. Neither pattern carries conviction as a directional signal. Institutional holders are broadly stable, with BlackRock near 8.5% and Vanguard entities collectively holding around 9%, both adding marginally in the most recent filings.
The setup heading into October 20 is therefore one of contained but persistent bearish positioning against a options market that has pulled back from peak bullishness without tipping negative. The question the print will answer is whether July's procedure-volume softness was transient or structural, and how far along the da Vinci 5 ramp has come since then.
See the live data behind this article on ORTEX.
Open ISRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
